{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096362","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.776003+00:00","generated_at":"2026-05-31T09:48:27.777900+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SeaStar Medical Q2 net loss $3.2M; first commercial QUELIMMUNE sales in July","bullets":["Net loss $3.2M ($1.03/share) vs $2.4M ($4.10/share) in Q2 2023, driven by higher R&D and G&A.","First commercial sales of QUELIMMUNE for pediatric AKI in July 2024; launched with U.S. distribution partner.","Adult NEUTRALIZE-AKI trial enrolled 42 subjects at 9 sites; CMS granted Category B coverage for Medicare/Medicaid.","Completed $10M registered direct offering in July; cash ~$6.9M as of July 31 after reducing debt by $2.7M.","Board expanded with three new directors; expects adult PMA approval in H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096362","json":"https://secwatch.observer/filing/0000950170-24-096362.json","markdown":"https://secwatch.observer/filing/0000950170-24-096362.md","text":"https://secwatch.observer/filing/0000950170-24-096362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024096362/0000950170-24-096362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024096362/icu-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:48:27.777900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}